NMN Supplementation in Healthy Adults

Randomized, Placebo-Controlled, Dose‑Response Trial (2023)

🔬 Study Design

• Randomized, multicenter, double‑blind, placebo‑controlled
• N = 80 healthy adults (middle-aged)
• Four oral dose groups: 0 mg (placebo), 300 mg, 600 mg, 900 mg/day
• Duration: 60 days
• Primary: blood NAD⁺ levels; Secondary: 6‑min walk test, SF-36 health survey, HOMA-IR, safety/tolerability

✅ Key Findings

• All NMN doses significantly increased blood NAD⁺ vs placebo by Days 30 & 60 (p≤0.001)
• 600 mg and 900 mg yielded the highest NAD⁺ levels
• Participants reported improved physical performance (6‑min walk) & general health (SF‑36)
• No serious adverse events—well tolerated across doses

⚠️ Limitations & Considerations

• Duration only 60 days—longer studies needed
• Middle-aged, healthy population—results may differ in older or metabolically impaired individuals

🧠 Takeaway

Daily NMN supplementation (≥300 mg) safely and dose‑dependently boosted NAD⁺ and showed early signs of improved physical performance and general well‑being. This positions NMN as a promising NAD⁺ booster; further clinical trials (longer, diverse populations) are essential before mainstream therapeutic use.